CVS Caremark Reaches Settlement with FTC Over Insulin Pricing Practices
CVS Health's Caremark has settled with the Federal Trade Commission (FTC) over allegations it prioritized more expensive insulin versions to boost rebates, increasing costs for consumers. The settlement mandates changes in business practices such as favoring lower-cost drugs and passing savings on to clients.
Tickers: $CVS
Topics: FTC settlement insulin pricing pharmacy benefit manager